$17.94
2.52% today
Nasdaq, Feb 28, 04:24 pm CET
ISIN
US9183851057
Symbol
VTVT
Sector
Industry

vTv Therapeutics, Inc. Class A Stock price

$18.40
+4.30 30.50% 1M
+1.77 10.64% 6M
+4.59 33.25% YTD
+9.90 116.47% 1Y
-14.34 43.81% 3Y
-131.60 87.73% 5Y
-417.20 95.78% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.24 1.29%
ISIN
US9183851057
Symbol
VTVT
Sector
Industry

Key metrics

Market capitalization $48.07m
Enterprise Value $9.62m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 9.62
P/S ratio (TTM) P/S ratio 48.07
P/B ratio (TTM) P/B ratio 3.20
Revenue growth (TTM) Revenue growth 11,011.11%
Revenue (TTM) Revenue $1.00m
EBIT (operating result TTM) EBIT $-24.00m
Free Cash Flow (TTM) Free Cash Flow $-23.40m
Cash position $41.57m
EPS (TTM) EPS $-4.53
P/S forward 48.07
EV/Sales forward 9.62
Short interest 3.33%
Show more

Is vTv Therapeutics, Inc. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

vTv Therapeutics, Inc. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast vTv Therapeutics, Inc. Class A:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast vTv Therapeutics, Inc. Class A:

Buy
100%

Financial data from vTv Therapeutics, Inc. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1 1
9,900% 9,900%
100%
- Direct Costs 0.09 0.09
0% 0%
9%
0.91 0.91
1,238% 1,238%
91%
- Selling and Administrative Expenses 13 13
16% 16%
1,346%
- Research and Development Expense 11 11
26% 26%
1,136%
-24 -24
12% 12%
-2,391%
- Depreciation and Amortization 0.09 0.09
0% 0%
9%
EBIT (Operating Income) EBIT -24 -24
12% 12%
-2,400%
Net Profit -18 -18
15% 15%
-1,831%

In millions USD.

Don't miss a Thing! We will send you all news about vTv Therapeutics, Inc. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

vTv Therapeutics, Inc. Class A Stock News

Neutral
PRNewsWire
3 months ago
WESTON, Fla. , Dec. 9, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Cantex's azeliragon for the treatment of brain metastasis from breast cancer.
Neutral
GlobeNewsWire
3 months ago
HIGH POINT, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today announced that management will participate in a fireside chat and be available for one-on-one meetings at the 7th Annual Evercore HealthCONx Conference to be held in Coral Gables. Flor...

Company Profile

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

Head office United States
CEO Paul Sekhri
Employees 16
Founded 2015
Website www.vtvtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today